Skip to main content
Equibles
CVSI logo

CVSI · CV Sciences, Inc. · Metrics

Track CVSI — free

Use CVSI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CVSI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.01 0.00 (-10.71%) At close · Oct 20
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.”
View the 10-Q filed Aug 13, 2026
Market Cap
$2.26M
Shares
225.83M
Volume · Oct 20 2.36M Avg daily vol (3M) 542.99K

CVSI metrics

81 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.01
Market cap
$2.26M

Price action

20 metrics
Price change (1W)
-30.6%
Price change (30D)
-31.5%
Price change (3M)
-50.0%
Price change (6M)
-66.7%
Price change (YTD)
-83.3%
Price change (1Y)
-75.0%
Trailing year
Price change (5Y)
-95.5%
52-week high
$0.09
52-week low
$0.01
Change from 52-week high
-88.9%
Change from 52-week low
+0.0%
Annualized volatility
227.3%
Annualized volatility (3M)
184.1%
Beta
1.4
RSI (14D)
36.2
Price vs SMA 50
-39.5%
Price vs SMA 200
-67.4%
Avg volume (3M)
542,993
Relative volume
4.3
Average dollar volume
$8,950

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
225.83M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.2×
reciprocal yield 633.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.2×
reciprocal yield 564.3%
P / book
1.4
reciprocal yield 69.6%
FCF yield
-23.1%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-88.8%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.5×
reciprocal yield 220.6%
EV / revenue historical average (5Y)
0.6×
reciprocal yield 165.1%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-13

Profitability

9 metrics
Gross margin
49.1%
Operating margin
-7.6%
Trailing 12 months
Net margin
-15.7%
Gross profit (TTM)
$6.26M
Operating profit (TTM)
−$969,000
Net income (TTM)
−$2.01M
Trailing 12 months
Diluted EPS (TTM)
$-0.01
FCF margin
-4.1%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.07
Gross profit per diluted share (TTM)
$0.03
Operating profit per diluted share (TTM)
$-0.01
EBITDA per diluted share (TTM)
$0.00
Net income per diluted share (TTM)
$-0.01
Operating cash flow per diluted share (TTM)
$0.00
Free cash flow per diluted share (TTM)
$0.00
Capital expenditures per diluted share (TTM)
$0.00
R&D per diluted share (TTM)
$0.00
Stock compensation per diluted share (TTM)
$0.00
Book value per share
$0.01

Growth

11 metrics
Revenue growth YoY
-17.5%
Year over year
Net income growth YoY
—
Revenue (TTM)
$12.74M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+11.3%
Year over year · more shares
Revenue CAGR (3Y)
-5.2%
Revenue CAGR (5Y)
-10.8%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-127.7%
Return on assets
-30.8%
Debt / equity
0.0
Current ratio
1.0
EBITDA (TTM)
−$872,000
Free cash flow (TTM)
−$522,000
Quick ratio
0.2
Interest coverage
-2.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$248,000
Latest balance sheet
Cash & equivalents
$266,000
Total assets
$6.52M
Total debt
$18,000

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$492,000
Capital expenditures (TTM)
$30,000
R&D (TTM)
$78,000
SG&A (TTM)
$7.15M
Stock compensation (TTM)
$543,000
R&D / revenue
0.6%
Stock compensation / revenue
4.3%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.0%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
22 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1510964 CUSIP 126654102 Visit website Investor relations